Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia.
Schmoellerl J, Barbosa IAM, Eder T, Brandstoetter T, Schmidt L, Maurer B, Troester S, Pham HTT, Sagarajit M, Ebner J, Manhart G, Aslan E, Terlecki-Zaniewicz S, Van der Veen C, Hoermann G, Duployez N, Petit A, Lapillonne H, Puissant A, Itzykson R, Moriggl R, Heuser M, Meisel R, Valent P, Sexl V, Zuber J, Grebien F. Schmoellerl J, et al. Among authors: puissant a. Blood. 2020 Jul 23;136(4):387-400. doi: 10.1182/blood.2019003267. Blood. 2020. PMID: 32344427 Free PMC article.
Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.
Ali A, Penneroux J, Dal Bello R Jr, Massé A, Quentin S, Unnikrishnan A, Hernandez L, Raffoux E, Ben Abdelali R, Renneville A, Preudhomme C, Pimanda J, Dombret H, Soulier J, Fenaux P, Clappier E, Adès L, Puissant A, Itzykson R. Ali A, et al. Among authors: puissant a. Leukemia. 2018 Aug;32(8):1856-1860. doi: 10.1038/s41375-018-0076-2. Epub 2018 Feb 26. Leukemia. 2018. PMID: 29535430 No abstract available.
BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.
Massé A, Roulin L, Pasanisi J, Penneroux J, Gachet S, Delord M, Ali A, Alberdi A, Berrou J, Passet M, Hernandez L, Quentin S, Gardin C, Raffoux E, Adès L, Braun T, Soulier J, Clappier E, Dombret H, Puissant A, Itzykson R. Massé A, et al. Among authors: puissant a. Leuk Res. 2019 Dec;87:106269. doi: 10.1016/j.leukres.2019.106269. Epub 2019 Nov 7. Leuk Res. 2019. PMID: 31751766
Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer.
Lin KH, Rutter JC, Xie A, Pardieu B, Winn ET, Bello RD, Forget A, Itzykson R, Ahn YR, Dai Z, Sobhan RT, Anderson GR, Singleton KR, Decker AE, Winter PS, Locasale JW, Crawford L, Puissant A, Wood KC. Lin KH, et al. Among authors: puissant a. Nat Genet. 2020 Apr;52(4):408-417. doi: 10.1038/s41588-020-0590-9. Epub 2020 Mar 16. Nat Genet. 2020. PMID: 32203462 Free PMC article.
Endothelial cells: major players in acute myeloid leukaemia.
Fodil S, Arnaud M, Vaganay C, Puissant A, Lengline E, Mooney N, Itzykson R, Zafrani L. Fodil S, et al. Among authors: puissant a. Blood Rev. 2022 Jul;54:100932. doi: 10.1016/j.blre.2022.100932. Epub 2022 Feb 2. Blood Rev. 2022. PMID: 35148910 Review.
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.
Pardieu B, Pasanisi J, Ling F, Dal Bello R, Penneroux J, Su A, Joudinaud R, Chat L, Wu HC, Duchmann M, Sodaro G, Chauvel C, Castelli FA, Vasseur L, Pacchiardi K, Belloucif Y, Laiguillon MC, Meduri E, Vaganay C, Alexe G, Berrou J, Benaksas C, Forget A, Braun T, Gardin C, Raffoux E, Clappier E, Adès L, de Thé H, Fenaille F, Huntly BJ, Stegmaier K, Dombret H, Fenouille N, Lobry C, Puissant A, Itzykson R. Pardieu B, et al. Among authors: puissant a. Leukemia. 2022 Jun;36(6):1585-1595. doi: 10.1038/s41375-022-01573-6. Epub 2022 Apr 26. Leukemia. 2022. PMID: 35474100
Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms.
Arnaud M, Loiselle M, Vaganay C, Pons S, Letavernier E, Demonchy J, Fodil S, Nouacer M, Placier S, Frère P, Arrii E, Lion J, Mooney N, Itzykson R, Djediat C, Puissant A, Zafrani L. Arnaud M, et al. Among authors: puissant a. J Am Soc Nephrol. 2022 Jun;33(6):1154-1171. doi: 10.1681/ASN.2021070997. Epub 2022 May 6. J Am Soc Nephrol. 2022. PMID: 35523579 Free PMC article.
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
Lin KH, Rutter JC, Xie A, Killarney ST, Vaganay C, Benaksas C, Ling F, Sodaro G, Meslin PA, Bassil CF, Fenouille N, Hoj J, Washart R, Ang HX, Cerda-Smith C, Chaintreuil P, Jacquel A, Auberger P, Forget A, Itzykson R, Lu M, Lin J, Pierobon M, Sheng Z, Li X, Chilkoti A, Owzar K, Rizzieri DA, Pardee TS, Benajiba L, Petricoin E, Puissant A, Wood KC. Lin KH, et al. Among authors: puissant a. Nat Cancer. 2022 Jul;3(7):837-851. doi: 10.1038/s43018-022-00394-x. Epub 2022 Jun 6. Nat Cancer. 2022. PMID: 35668193 Free PMC article.
301 results